Acceleron Pharma — Investor Day (October 2015)
92 slides from Acceleron Pharma's investor day presentation, Oct 23, 2015
Slide 1: Acceleron Pharma R&D Day October 23, 2015
Acceleron Pharma R&D Day October 23, 2015 1 Exhibit 99.1
Slide 2: Welcome and Agenda
Welcome and Agenda Todd James Senior Director, Corporate Communications Acceleron 2
Slide 3: Forward-Looking Statements
Acceleron Forward-Looking Statements 3 This presentation contains forward-looking statements about the Company's strategy, future plans and prospects, including statements regarding the development of the Company's compounds, including sotatercept, luspatercept, dalantercept, ACE-083, ACE-2494, the
Slide 4: Agenda
Agenda 4 R&D Strategy John Knopf, Ph.D. - Acceleron Chief Executive Officer ACE-083 and Muscle Franchise Matthew Sherman, M.D. - Acceleron Chief Medical Officer Anthony Amato, M.D. - Vice Chairman, Department of Neurology, Brigham and Women’s Hospital, Boston Dalantercept and Sotatercept Matthew She
Slide 5: Acceleron R&D Strategy
Acceleron R&D Strategy John Knopf, Ph.D. Chief Executive Officer Acceleron 5
Slide 6: Driven to Make a Difference
Driven to Make a Difference Dedicated to improving the lives of patients with serious, underserved diseases Apply the biology of the TGF-beta superfamily to internally discover and develop innovative therapeutics Efficiently and rapidly build a multi-product company Hire the best people in t
Slide 7: Acceleron R&D Strategy
Acceleron R&D Strategy The human body has a remarkable ability to regenerate, rebuild and repair itself The TGF-beta superfamily of proteins can profoundly influence many of these biological processes Acceleron has pioneered a new approach to engage these targets for therapeutic benefit 7
Slide 8: Targeting a Wide Range of Diseases
Targeting a Wide Range of Diseases Our deep scientific knowledge, extensive clinical development experience and commitment to this area of biology enable us to create important new medicines that can have profound effects on a wide range of diseases 8 TGF-β Superfamily Biology Skeletal Muscle Osteog
Slide 9: Signaling in the TGF-beta Superfamily
Signaling in the TGF-beta Superfamily The TGF-beta superfamily is a large and diverse group of proteins (30 ligands, 12 receptors and 10 ligands traps) The 30 ligands signal by binding to a pair of receptor subtypes (one type I paired to one type II receptor) Several different ligands can sign
Slide 10: Acceleron Initial Drug Discovery Approach
Acceleron Initial Drug Discovery Approach Acceleron’s first wave of therapeutics was based on creating receptor fusion proteins to inhibit the binding of multiple ligands to their receptors Sotatercept and dalantercept are two such examples – Sotatercept is based on the activin type IIA receptor
Slide 11: Initial Approach in the Muscle Area
Initial Approach in the Muscle Area TGF-beta superfamily ligands are key targets for rebuilding muscle ActRIIB receptor fusion protein inhibits multiple negative regulators of muscle (myostatin and activin) and is a potent stimulator of muscle mass But, ActRIIB receptor fusion protein also bin
Slide 12: IntelliTrap Platform – The Solution to Achieve Optimal Ligand Binding Specificity
IntelliTrap™ Platform – The Solution to Achieve Optimal Ligand Binding Specificity Acceleron’s knowledge of the TGF-beta superfamily combined with our exceptional capabilities in protein engineering led to the creation of the IntelliTrap™ Platform The IntelliTrap™ Platform enables Acceleron to s
Slide 13: ACE-2494, an Optimized Muscle Agent, from the IntelliTrap Platform
ACE-2494, an Optimized Muscle Agent, from the IntelliTrap™ Platform ACE-2494 binds to myostatin (GDF8) and activins with high affinity thus selectively trapping the negative regulators of muscle mass ACE-2494 binding to BMP9 (involved in blood vessel maturation) is dramatically reduced relative
Slide 14: ACE-2494 Generates Profound Increases in Muscle Mass
ACE-2494 Generates Profound Increases in Muscle Mass 14 In a one-month study in mice, ACE-2494 increases muscle mass comparable to ActRIIB-Fc Data presented at 20th International Annual Congress of World Muscle Society on October 1, 2015 These increases far exceed the 15-20% increases observed with
Slide 15: IntelliTrap Platform Creates Large and Diverse Library of New, Selective Therapeutic Candidates
ActRIIBFc ACE-2798 ACE-2395 ACE-2494 IntelliTrap™ Platform Creates Large and Diverse Library of New, Selective Therapeutic Candidates 15 + + - - Activin A + + + - Activin B + + + - GDF8 + - - - BMP9 - - - + BMP2 Three highly distinct molecules all derived from the ActRIIB receptor were created from
Slide 16: Expanding Platforms for Success
Expanding Platforms for Success Acceleron designs distinct constructs to optimally target selected molecules Receptor fusion proteins (sotatercept and dalantercept) Modified receptor fusion proteins (luspatercept) Natural ligand traps modified to be locally acting (ACE-083) IntelliTrap™ mole
Slide 17: Acceleron Muscle Franchise
Acceleron Muscle Franchise Matthew Sherman, M.D. Chief Medical Officer Acceleron 17
Slide 18: Acceleron Muscle Franchise
Acceleron Muscle Franchise 18 Acceleron’s muscle franchise and ACE-083 Phase 1 results Matthew Sherman, M.D. Chief Medical Officer, Acceleron Opportunities in neuromuscular diseases Anthony Amato, M.D. Vice Chairman, Department of Neurology Chief, Neuromuscular Division Brigham and Women’s Hospital,
Slide 19: Portfolio of Differentiated Muscle Programs
ACE-3891 Acceleron is Developing a Portfolio of Differentiated Muscle Programs 19 ACE-083 Diseases of Focal Muscle Loss ACE-2494 Diseases of Systemic Muscle Loss FSHD DMD sIBM LGMD CMT ALS Cerebral Palsy Peripheral Nerve Trauma Disuse Atrophy Stroke Aesthetic Common Disorders with Muscle Loss Rare M
Slide 20: ACE-083: For Diseases Involving Focal Muscle Loss
ACE-083: For Diseases Involving Focal Muscle Loss ACE-083 is derived from one of the 10 naturally occurring TGF-beta superfamily ligand traps ACE-083 is designed to increase muscle mass and strength selectively in the muscles in which the drug is administered ACE-083 binds to and inhibits acti
Slide 21: ACE-083 Phase 1 Study in Healthy Volunteers
ACE-083 Phase 1 Study in Healthy Volunteers Study Description Randomized, double-blind, placebo-controlled, dose-ranging study in healthy volunteers Objectives of the Study To evaluate the safety and tolerability of single and multiple doses of ACE-083 as a local muscle injection To evaluate t
Slide 22: ACE-083 Phase 1 Study Design
ACE-083 Phase 1 Study Design 22 Number of Doses Cohort Dosing Day(s) Dose Level (mg) Injected Muscle ACE-083 Subjects Placebo Subjects Status Single Dose 1 Day 1 50 Rectus Femoris 6 2 Completed 2 Day 1 100 Rectus Femoris 6 2 3 Day 1 200 Rectus Femoris 6 2 Multiple Doses 4 Days 1, 22 100 Rectus Femor
Slide 23: ACE-083 Administered to Rectus Femoris Muscle
ACE-083 Administered to Rectus Femoris Muscle 23 MRI at baseline, 3 and 8 weeks post last dose, determined muscle volume
Slide 24: ACE-083 Produced Substantial Dose-Dependent Increases in Muscle Volume
ACE-083 Produced Substantial Dose-Dependent Increases in Muscle Volume 24 ACE-083 generated a 14.5% increase in muscle at the top dose level
Slide 25: ACE-083 Generated Increases in Muscle Volume Not Previously Seen
ACE-083 Generated Increases in Muscle Volume Not Previously Seen with Any Other Muscle Compound 25 Data from reported phase 1 results except for bimagrumab data, which is from its phase 2 trials in sarcopenia and sIBM 2-4% increase 6-8% increase 14% increase GDF8-specific agents Antibody to ActRIIA
Slide 26: ACE-083 Phase 1 Summary
ACE-083 Phase 1 Summary ACE-083 was well-tolerated Robust dose dependent increases in muscle volume Magnitude of increases in muscle volume not previously seen in human clinical trials of any other muscle therapeutic Exciting and highly differentiated product opportunity for patients sufferi
Slide 27: Diseases of Focal Muscle Loss: Opportunities For ACE-083
Diseases of Focal Muscle Loss: Opportunities For ACE-083 27 Images from Muscular Dystrophy Association USA Facioscapulohumeral Muscular Dystrophy Non-Ambulatory Duchenne Muscular Dystrophy Biceps Tibialis Anterior
Slide 28: ACE-083: Initiate Phase 2 in FSHD Patients in Mid-2016
ACE-083: Initiate Phase 2 in FSHD Patients in Mid-2016 FSHD is one of the most prevalent forms of muscular dystrophy affecting roughly 19,000 patients in the U.S. Substantial unmet medical need Acceleron intends to initiate a Phase 2 study of ACE-083 in patients with FSHD in mid-2016 28
Slide 29: Opportunities in Rare Muscle Disorders
Opportunities in Rare Muscle Disorders Anthony Amato, M.D. Vice Chairman, Department of Neurology Chief, Neuromuscular Division Brigham and Women’s Hospital Boston, MA 29
Slide 30: Spectrum of Neuromuscular Disorders
Spectrum of Neuromuscular Disorders 30 Myopathies Neurogenic Neuromuscular Junction Disorders Involve dysfunction of the peripheral nerves, which consist of motor neurons that carry electrical signals directly from the spinal cord and brain stem to activate muscle movement Can be a mix of upper
Slide 31: Spectrum of Neuromuscular Disorders
Spectrum of Neuromuscular Disorders Facioscapulohumeral MD (FSHD) Dystrophinopathies – Duchenne MD (DMD) – Becker MD (BMD) Limb Girdle MD (LGMD) – Autosomal Dominant LGMD1A – 1F – Autosomal Recessive LGMD2A – 2S Emery Dreifuss MD (EDMD) Distal Dystrophies Oculopharyngeal MD (OPMD) Myot
Slide 32: Facioscapulohumeral Muscular Dystrophy (FSHD)
Facioscapulohumeral Muscular Dystrophy (FSHD) 32 PRONOUNCED DISEASE NAME Comes from the typical pattern of weakness at onset Facio • the face Scapulo • shoulder blade Humeral • upper arms A clinically defining feature of the disease is its effects on the tibialis anterior muscle in the lower leg fā'
Slide 33: FSHD Disease Description
FSHD Disease Description Severe, disabling, and painful skeletal muscle disease Distinct presentation with muscle-by-muscle progression Muscle weakness can be heterogeneous, but is highly focal and primarily asymmetric Typical onset is in the 20-30’s with most FSHD patients living a normal l
Slide 34: Diagnosis of FSHD
Diagnosis of FSHD Clinical Evaluation Review of family history and cardinal symptoms Blood Tests Serum CK Muscle Biopsies Might reveal abnormalities, but no unique characteristics for FSHD Genetic Test (gold standard) FSHD1 (95% of cases) are commercially available and are 98% reliable FSH
Slide 35: FSHD Patients Epidemiology
0 10 20 30 40 FSHD Patients 35 Epidemiology Roughly 19,000 patients in the U.S. Affects males and females equally Autosomal dominant; ~30% with no family history; Carriers may be “non-manifesting” Prevalence by Age Group # pe r m ill io n Photos care of FSH Society
Slide 36: FSHD Muscle Weakness Presentation
FSHD Muscle Weakness Presentation 36 ~20% become non-ambulatory Lordosis Positive Beevor’s sign Ankle dorsiflexion weakness Profound scapular winging 95% facial weakness at 30 yo Biceps/Triceps affected early Deltoids often spared Pectoralis major limits upper body function Photos care of MDA, FSH S
Slide 37: FSHD Muscle Weakness Presentation
FSHD Muscle Weakness Presentation 37 ~20% become non-ambulatory Lordosis Positive Beevor’s sign Ankle dorsiflexion weakness Profound scapular winging 95% facial weakness at 30 yo Biceps/Triceps affected early Deltoids often spared Pectoralis major limits upper body function Photos care of MDA, FSH S
Slide 38: Improvements in Tibialis Anterior and Biceps Strength Would Provide Clinical Benefit
Improvements in Tibialis Anterior and Biceps Strength Would Provide Clinical Benefit to FSHD Patients 38 Critical muscle involved in ankle dorsiflexion Weakness of this muscle causes foot drop, impairs ambulation and increases risk of falls Foot drop is often a key symptom at presentation St
Slide 39: Duchenne Muscular Dystrophy (DMD) Disease Overview
Duchenne Muscular Dystrophy (DMD) Disease Overview 39 Pathology Severe skeletal muscle disease affecting mostly boys with well-defined disease course and features Rapidly progressive weakness and contractures leads to loss of ambulation by early teens Eventually results in early death due to r
Slide 40: DMD – Chronology of Clinical Features
0 5 10 15 20 25 30 Predictable loss of muscle function in ambulatory and non-ambulatory stages Patient Age DMD – Chronology of Clinical Features Motor Development Delay Ambulation Deterioration, Trunk Weakness, Fatigue Loss of Ambulation, Scoliosis Limited Used of Arms Cardiac & Pulmonary Complicati
Slide 41: Dalantercept
Dalantercept Matthew Sherman, M.D. Chief Medical Officer Acceleron 41
Slide 42: Dalantercept in Renal Cell Carcinoma (RCC)
Dalantercept in Renal Cell Carcinoma (RCC) Renal cell carcinoma is a highly angiogenic tumor Anti-angiogenesis therapies have shown and continue to show robust efficacy in RCC Substantial opportunity for a new drug to build upon, not compete with, large established base of numerous approved VE
Slide 43: Dalantercept plus axitinib data demonstrate proof of concept
43 Median PFS (months) Dalantercept plus axitinib data demonstrate proof of concept * PFS analyses were based on investigator assessment of radiologic progression (i.e. no central read) ** PFS in patients who received prior sunitinib Median Progression Free Survival (PFS) Patients ≥ 1 Prior VEGFR TK
Slide 44: Median Progression Free Survival (PFS)
Median Progression Free Survival (PFS) Patients ≥ 1 Prior VEGFR TKI (2nd Line+ RCC Studies) 44 0 1 2 3 4 5 6 7 8 9 10 Sorafenib (AXIS) Everolimus (METEOR) Everolimus (CheckMate-025)* Nivolumab (CheckMate-025)* Axitinib (AXIS)** Cabozantinib (METEOR) Dalantercept + Axitinib (DART Part 1)* 3.6 3.8 4.4
Slide 45: Objective Response Rates (ORR)
45 0% 5% 10% 15% 20% 25% 30% Everolimus (METEOR) Everolimus (CheckMate-025)* Sorafenib (AXIS) Axitinib (AXIS) Cabozantinib (METEOR) Nivolumab (CheckMate-025)* Dalantercept + Axitinib (DART Part 1)* 5% 5% 8% 11% 21% 25% 25% Objective Response Rate (%) Objective Response Rates (ORR) Patients ≥ 1 Prior
Slide 46: 12-Month Progression Free Survival Rates
46 0% 5% 10% 15% 20% 25% 30% 35% 40% Everolimus (METEOR) Everolimus (CheckMate-025)* Sorafenib (AXIS) Nivolumab (CheckMate-025)* Axitinib (AXIS)** Cabozantinib (METEOR) Dalantercept + Axitinib (DART Part 1)* 15% 19% 20% 23% 25% 30% 39% 12-Month Progression Free Survival Rates Patients ≥ 1 Prior VEGF
Slide 47: Dalantercept in Renal Cell Carcinoma
Dalantercept in Renal Cell Carcinoma Dalantercept in combination with axitinib in Part 1 of the DART study produced clinical outcomes that exceed historical axitinib results Dalantercept safety profile was generally non-overlapping with VEGFR TKI and well-tolerated Enrollment ongoing in Part 2
Slide 48: Sotatercept in Chronic Kidney Disease
Sotatercept in Chronic Kidney Disease John Knopf, Ph.D. Chief Executive Officer Acceleron 48
Slide 49: Sotatercept in Chronic Kidney Disease (CKD)
Sotatercept in Chronic Kidney Disease (CKD) Data presentations at American Society of Nephrology Kidney Week 49 Hemoglobin Effects “Safety and Hemoglobin Effect of Sotatercept, Administered Intravenously and Subcutaneously, for Maintenance of Hemoglobin in Hemodialysis Subjects: Interim Analysis o
Slide 50: Sotatercept Future Development Plan in CKD
Sotatercept Future Development Plan in CKD Refocus clinical development strategy from CKD dialysis to treatment of pre-dialysis CKD to better align with… – Preclinical and clinical activity on vascular calcification and renal fibrosis – Large patient population – Preferred reimbursement / access e
Slide 51: Question & Answer Session
Question & Answer Session 51 John Knopf, Ph.D. Chief Executive Officer Acceleron Matthew Sherman, M.D. Chief Medical Officer Acceleron Anthony Amato, M.D. Vice Chairman, Department of Neurology Chief, Neuromuscular Division Brigham and Women’s Hospital Boston, MA Steven Ertel Chief Operating Officer
Slide 52: Beta-thalassemia and MDS Sessions
Beta-thalassemia and MDS Sessions Steven Ertel Chief Operating Officer Acceleron 52
Slide 53: Beta-thalassemia and MDS Sessions
Beta-thalassemia and MDS Sessions 53 Beta-thalassemia landscape and opportunity for luspatercept M. Domenica Cappellini, M.D. Director of the Department of Clinical Sciences Director of the Unit of Internal Medicine University of Milan Luspatercept Phase 3 program Jay Backstrom, M.D. M.P.H. Senior V
Slide 54: Beta-thalassemia
Beta-thalassemia M. Domenica Cappellini, M.D. Director of the Department of Clinical Sciences, Director of the Unit of Internal Medicine, University of Milan, Italy 54
Slide 55: Beta-thalassemia Disease Description
Beta-thalassemia Disease Description Beta-thalassemia is an inherited disorder resulting in severe and chronic anemia, often beginning in the first years of life Genetic defect impacts production of hemoglobin and results in ineffective erythropoiesis (inability of red blood cells (RBC) cells to
Slide 56: Beta-thalassemia is a Global Disease
Beta-thalassemia is a Global Disease Estimates capture predominantly RBC transfusion-dependent patients We believe there are at least as many non-transfusion dependent patients in the U.S. and Europe who have no therapeutic options 56 Estimated prevalence of transfusion-dependent beta-thalassemi
Slide 57: Complications of Beta-thalassemia
Complications of Beta-thalassemia 57 Symptom Consequences Ineffective erythropoiesis EPO overproduction, bone marrow expansion Premature death of erythroid progenitor cells Bone deformities, osteoporosis, fractures Extramedullary hematopoietic masses Hemolysis Enlarged spleen (may require
Slide 58: Current Treatment Options
Current Treatment Options Red blood cell transfusions Iron chelation therapy Hematopoietic stem cell transplant 58
Slide 59: Red Blood Cell Transfusions in Beta-thalassemia
Red Blood Cell Transfusions in Beta-thalassemia Backbone of treatment for all patients Patients who currently do not depend on regular transfusions for survival may become transfusion dependent due to complications, especially as they age, or physician may switch to transfusions to prevent compl
Slide 60: Unmet Need in Beta-thalassemia
Unmet Need in Beta-thalassemia 60 Anemia Iron Overload Disease Complications No effective therapies to treat – Persistent leg ulcers – Splenomegaly – Endocrine disorders – Pulmonary hypertension Chronic and often significant anemia is unresponsive to any drug therapy RBC transfusions inconveni
Slide 61: Luspatercept Phase 2 Study (NTD and TD patients)
0 2 4 6 8 10 12 14 16 18 20 >20 Non-Transfusion Dependent (NTD) ~20,000 in US/EU Transfusion Dependent (TD) ~20,000 in US/EU Transfusions per year Luspatercept Phase 2 Study (NTD & TD patients) Luspatercept Phase 2 Study (NTD and TD patients) NTD patients experienced sustained increases in total h
Slide 62: Luspatercept Reduced Transfusion Burden
Luspatercept Reduced Transfusion Burden Of the 14 transfusion dependent patients, 10 were treated for ≥12 weeks and were evaluable for change in transfusion burden All 10 of these patients had >40% reduction in transfusion burden over 12 weeks Results presented at EHA June 2015 -100 -80 -60 -40
Slide 63: Luspatercept Phase 3 Study in Beta-thalassemia
63 Luspatercept Phase 3 Study in Beta-thalassemia Jay Backstrom, M.D. M.P.H. Senior Vice President, Hematology & Oncology R&D, Global Head Regulatory Affairs, Celgene
Slide 64: The BELIEVE Study
The BELIEVE Study Phase 3 study of luspatercept in beta-thalassemia Phase 3, double-blind, randomized, placebo-controlled study of luspatercept in regularly transfused beta-thalassemia patients 64
Slide 65: The BELIEVE Study: Patient Population and Study Design
The BELIEVE Study Phase 3 study of luspatercept in beta-thalassemia 65 Patient Population Study Design Key Inclusion Criteria Adult beta-thalassemia patients who are regularly transfused Randomized, double-blind, placebo-controlled 300 patients, randomized 2:1 12-week prospective pre-treatment perio
Slide 66: The BELIEVE Study: Efficacy Analyses and Dose
The BELIEVE Study Phase 3 study of luspatercept in beta-thalassemia 66 Primary Efficacy Analysis Key Secondary Efficacy Analysis Luspatercept Dose / Regimen Proportion of patients with ≥ 33% reduction in transfusion burden from weeks 13-24 compared to the 12 weeks preceding treatment Proportion of p
Slide 67: BELIEVE Trial Focuses on Regularly Transfused Beta-thalassemia Patients
0 2 4 6 8 10 12 14 16 18 20 >20 Non-Transfusion Dependent (NTD) Transfusion Dependent (TD) Transfusions per year Luspatercept Phase 3 BELIEVE Study Luspatercept Phase 3 BELIEVE Trial Focuses on the Regularly Transfused Beta-thalassemia Patients 67 Occasionally Transfused Regularly Transfused Heavily
Slide 68: Beta-thalassemia Phase 3 Trial Similar to Phase 2 with Enhancements
Beta-thalassemia Phase 3 Trial Similar to Phase 2 with Several Important Enhancements 68 Phase 2 Phase 3 Patient Population Anemic, non-transfusion dependent patients (0 - 12 units/24 weeks) and transfusion dependent patients (≥ 12 units/ 24 weeks) Regularly transfused patients: transfusion burden f
Slide 69: Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes (MDS) 69
Slide 70: Myelodysplastic Syndromes
Myelodysplastic Syndromes Uwe Platzbecker, M.D. Professor of Hematology and Head of the MDS Program University Hospital Dresden, Germany 70
Slide 71: Myelodysplastic Syndromes (MDS) Disease Description
Myelodysplastic Syndromes (MDS) Disease Description Hematologic malignancy resulting in multiple cytopenias (anemia, neutropenia, thrombocytopenia) – Patients classified by risk (very low - > very high) of progression to AML – Roughly 100,000 lower risk MDS patients in the U.S. and E.U. Disease
Slide 72: MDS Treatment Algorithm
Myelodysplastic Syndromes (MDS) Treatment Algorithm 72 Many patients try ESAs, but the majority do not respond Some patients are identified as unlikely to respond (EPO > 200) and are not eligible for ESA therapy RBC transfusions are a mainstay of therapy to manage anemia Transfusions are bur
Slide 73: Unmet Need in Lower Risk MDS
Unmet Need in Lower Risk MDS There are limited treatment options to treat anemia that are suitable for the lower risk MDS patients There is substantial unmet medical need for safe and well-tolerated drugs that can be used early in the treatment algorithm to avoid or reduce red blood cell transfu
Slide 74: Luspatercept Phase 2 Study in Lower Risk MDS
Luspatercept Phase 2 Study in Lower Risk MDS Key eligibility criteria: – Lower risk MDS – Nonresponsive or refractory to prior ESA treatment – No prior ESA treatment or ESA ineligible (EPO >500 U/L) – No prior azacitidine or decitabine – No current lenalidomide, ESA, G-CSF Luspatercept treatment
Slide 75: Hemoglobin Patient in the Luspatercept Phase 2 Study
2 2 0 2 4 6 8 10 12 5 6 7 8 9 10 11 -3 BL 3 6 9 12 16 20 24 Units Transfused Hemoglobin Patient in the Luspatercept Phase 2 Study Data presented at ASH 2014 75 Weeks He m ogl o b in ( g /d L) Follow-up Period 0.75 mg/kg (starting dose) 71 year old female; RCMD-RS; Failed LEN, EPO
Slide 76: Luspatercept Phase 2 Results and Perspective
Luspatercept Phase 2 Results and Perspective Data presented at EHA 2015 With only 12 weeks of treatment, 11/30 (37%) patients achieved RBC-transfusion independence Longer-term treatment maintained transfusion independence A biomarker (ring sideroblasts) associated with ineffective erythropoies
Slide 77: Luspatercept Phase 3 Study in MDS
77 Luspatercept Phase 3 Study in MDS Jay Backstrom, M.D. M.P.H. Senior Vice President, Hematology & Oncology R&D, Global Head Regulatory Affairs, Celgene
Slide 78: The MEDALIST Study
The MEDALIST Study Phase 3 study of luspatercept in MDS Phase 3, double-blind, randomized, placebo-controlled study of luspatercept in very low to intermediate risk myelodysplastic syndromes patients 78
Slide 79: The MEDALIST Study: Patient Population and Study Design
The MEDALIST Study Phase 3 study of luspatercept in MDS 79 Patient Population Study Design Key Inclusion Criteria Very low, low or intermediate risk MDS patients with ring sideroblasts who require RBC transfusions Randomized, double-blind, placebo-controlled 210 patients, randomized 2:1 (140 luspate
Slide 80: The MEDALIST Study: Efficacy Analyses and Dose
The MEDALIST Study Phase 3 study of luspatercept in MDS 80 Primary Efficacy Analysis Key Secondary Efficacy Analysis Luspatercept Dose / Regimen Proportion of patients that become RBC-transfusion independent (≥ 8 weeks) during the first 24 weeks Proportion of patients that become RBC-transfusion ind
Slide 81: MDS Phase 3 Trial Similar to Phase 2 with Enhancements
MDS Phase 3 Trial Similar to Phase 2 with Several Important Enhancements 81 Phase 2 Phase 3 Patient Population Lower risk MDS (RS+/-) Lower risk MDS (RS+) Key Inclusion Criteria Nonresponsive or refractory to prior ESA treatment No prior ESA treatment / ineligible (EPO >500 U/L) No prior azaci
Slide 82: Luspatercept Development Program in Beta-thalassemia and MDS
Luspatercept Development Program in Beta-thalassemia and MDS Steven Ertel Chief Operating Officer Acceleron 82
Slide 83: Vision for Luspatercept in Lower Risk MDS Patients Following MEDALIST
Vision for Luspatercept in Lower Risk MDS Patients Following MEDALIST Phase 3 Trial 83 ESA Treatment Naïve Lower Risk MDS patients Luspatercept lenalidomide del5q (~15%) Non-del5q (~85%) ESA Eligible? Yes (EPO≤200) No (EPO>200) lenalidomide azacitadine decitabine
Slide 84: Comprehensive Ongoing Luspatercept Phase 2 Program
Comprehensive Ongoing Luspatercept Phase 2 Program in Beta-thalassemia and MDS Concurrent with the Phase 3 Trials Beta-thalassemia Phase 2 long-term (up to 2 years) study MDS Phase 2 long-term (up to 2 years) study Phase 2 study – Treatment naïve patients – Ring sideroblast negative (RS-) pati
Slide 85: Question & Answer Session
Question & Answer Session 85 M. Domenica Cappellini, M.D. Director of the Department of Clinical Sciences Director of the Unit of Internal Medicine University of Milan Uwe Platzbecker, M.D. Professor of Hematology and Head of the MDS Program University Hospital Dresden, Germany Jay Backstrom, M.D. M
Slide 86: R&D Day Summary
R&D Day Summary Steven Ertel Chief Operating Officer Acceleron 86
Slide 87: R&D Day Highlights
R&D Day Highlights The luspatercept Phase 3 studies in MDS and beta-thalassemia, in partnership with Celgene, positions Acceleron closer to becoming a fully integrated biotech company Dalantercept data from Part 1 of the DART study provides proof of concept that combination of dalantercept plus
Slide 88: Upcoming 2015 Milestones and Events
Upcoming 2015 Milestones and Events 88 November 6-7 December 5-8 December 4-6 November 5-6 American Society of Nephrology Kidney Cancer Association’s 14th International Kidney Cancer Symposium Sarcopenia, Cachexia, Wasting Disorders Conference American Society of Hematology Start of luspatercept P
Slide 89: Acceleron is Building One of the Industry's Most Robust Clinical Pipelines
Acceleron is Building One of the Industry’s Most Robust Clinical Pipelines 89 Luspatercept - MDS Luspatercept - Thalassemia Sotatercept – CKD Sotatercept - Myelofibrosis Sotatercept – Myeloma ACE-083 - FSHD Dalantercept - RCC Dalantercept - HCC Phase 1 Sotatercept – DBA Phase 2 Phase 3 Four intern
Slide 90: And We're Just Getting Started…
And We’re Just Getting Started… 90 Luspatercept - MDS Luspatercept - Thalassemia Sotatercept – CKD Sotatercept - Myelofibrosis Sotatercept – Myeloma ACE-083 - FSHD Dalantercept - RCC Dalantercept - HCC Phase 1 Sotatercept – DBA Phase 2 Phase 3 Preclinical ACE-2494 ACE-3891 ACE-2798 ACE-2536 ACE-2395
Slide 91: Acceleron's 2020 Vision
Acceleron’s 2020 Vision Our highly productive discovery and development platform has the potential to transform Acceleron into one of the world’s leading biotechnology companies 91 Acceleron’s Goals for the Year 2020 Approvals in up to 5 indications Multiple phase 3 studies 8 therapeutic candidates
Slide 92: Thank You
Building One Of The World’s Great Biotechnology Companies www.acceleronpharma.com NASDAQ: XLRN 92 THANK YOU